Sugi Predict

Sugi Predict / Compounds / SCHEMBL902632

SCHEMBL902632

SCHEMBL902632

Oc1c(Cc2cc(F)cc(Cl)c2)c(C2CC2)nc2ccnn12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 2/20 0.37
▸ PDE4B Q07343 2/20 0.37
▸ PDE4C Q08493 2/20 0.37
▸ PDE4D Q08499 2/20 0.37
▸ CCR2 P41597 7/20 0.35
▸ CCR5 P51681 2/20 0.34
▸ MAPKAPK2 P49137 5/20 0.33
▸ KCNN3 Q9UGI6 2/20 0.33
▸ CDK2 P24941 3/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ MAPK9 P45984 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ MAP2K1 Q02750 1/20 0.33
▸ MAPKAPK5 Q8IW41 1/20 0.33
▸ KCNN1 Q92952 1/20 0.33
▸ KCNN2 Q9H2S1 1/20 0.33
▸ P2RX7 Q99572 1/20 0.32
▸ FAAH O00519 1/20 0.32
▸ MGLL Q99685 1/20 0.32
▸ PDE10A Q9Y233 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902501 0.93 CCR2 (0.38) CCR2CCR5MAPKAPK2KCNN3CDK2
SCHEMBL902561 0.92 CCR2 (0.37) PDE4APDE4BPDE4CPDE4DCCR2
SCHEMBL15274714 0.87 PDE2A (0.35) CCR2KCNN3CDK2PDE10A
SCHEMBL902260 0.86 MAPKAPK2 (0.40) CCR2CCR5MAPKAPK2CDK2ROCK2
SCHEMBL902809 0.86 CCR2 (0.49) PDE4APDE4BPDE4CPDE4DCCR2
SCHEMBL902108 0.85 CCR2 (0.34) CCR2MAPKAPK2KCNN3CDK2ROCK2
SCHEMBL902639 0.85 CCR2 (0.38) CCR2KCNN3GPR52
SCHEMBL902240 0.84 CCR2 (0.35) CCR2CCR5MAPKAPK2CDK2ROCK2
SCHEMBL902384 0.84 CCR2 (0.38) PDE4APDE4BPDE4CPDE4DCCR2
SCHEMBL15274723 0.83 PDE2A (0.38) CCR2KCNN3CDK2PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 — — US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 — — US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 — — US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 — — EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 PDE4A 1751/4885PDE4B 1694/4885PDE4C 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.